Fig. 5From: Tumor-targeting, Systemically Delivered Antisense HER-2 Chemosensitizes Human Breast Cancer Xenografts Irrespective of HER-2 LevelsComparison of intratumoral accumulation of intravenously administered free [35S]-labeled ODN or [35S]-labeled ODN complexed with F-Lip-2. Values given are CPM in 100 mg of tumor tissue. Time is hours after intravenous injection.Back to article page